TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03953950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone Starting dose: 25 mg/day Target dose: 100 mg/day Titration: every 1-2 weeks, based on BP (keep\< 140/90 mmHg, but avoid hypotension \<90/60 mmHg), and serum potassium level (\<5.5 milliequivalent /liter)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan Starting dose: 50 mg/day Target dose: 100 mg/day Titration: every 1-2 weeks, based on BP (keep\< 140/90 mmHg, but avoid hypotension \<90/60 mmHg), and serum potassium level (\<5.5 milliequivalent /liter)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Losartan Starting dose: 50 mg/day Target dose: 100 mg/day Titration: every 1-2 weeks, based on BP (keep\< 140/90 mmHg, but avoid hypotension \<90/60 mmHg), and serum potassium level (\<5.5 milliequivalent /liter)
Study: NCT01586611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU, leucovorin, oxaliplatin
Description: Oxaliplatin 100 mg/m2 IV day 1 Leucovorin 400 mg/m2 IV day 1 5-FUl 400 mg/m2 IV day 1 5-FU 2400 mg/m2 IV continuous infusion over 46 hours starting day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m2 IV weekly for 3 weeks then one week off
Study: NCT00599664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS201
Description: OMS201 irrigation solution during surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle irrigation solution during surgery
Study: NCT02661295

Intervention type: DRUG
Group type: OTHER
Intervention: Ferric Citrate
Description: Study participants will receive ferric citrate at a starting dose of 2 tablets with each meal if serum phosphorus levels are ≥ 6.0 mg/dL calcium levels are in the normal range, Tsat ≥ 20 and \< 50% and ferritin ≥ 200 and \< 500 ng/ml after a 2 week wash out period.
Study: NCT01194388

Intervention type: DEVICE
Intervention: MicroFx™ PGLA COILS
Description: . This observational evaluation will evaluate early experience using the Axium™ MicroFx™ Detachable Coils as compared to published literature of coils with electrolytic, thermal or hydraulic detachment process or the Axium™ bare Detachable Coils arm obtained from previous evaluation conducted following the same protocol.
Study: NCT01126125

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iodized oil
Description: 400 mg of iodine vs 100 mg of iodine as iodized oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iodized oil
Description: 400 mg of iodine vs 100 mg of iodine as iodized oil
Study: NCT01880307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolon
Study: NCT02000908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photobiomodulation
Description: The photobiomodulation delivered by Realief Therapy involves amplitude wavelength light delivered by a class IV therapeutic laser.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: photobiomodulation
Description: The photobiomodulation delivered by Realief Therapy involves amplitude wavelength light delivered by a class IV therapeutic laser.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: All patients in sham treatment arm cross over to laser therapy followed by physiotherapy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physiotherapy
Description: Chiropractic massage and lymphedema treatment
Study: NCT01410851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary treatment
Description: A within-subject, balanced repeated-measures design was followed where subjects received 4 treatments or control over 5 weeks approximately 1 week apart. The pulse treatments contained: (1) chickpeas (Primo, Toronto, ON), (2) lentils (Primo, Toronto, ON), (3) navy beans (Ferma, Toronto, ON) or (4) yellow peas (Nupak, Toronto, ON).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary treatment
Description: A within-subject, balanced repeated-measures design was followed where subjects received 4 treatments or control over 5 weeks approximately 1 week apart. The pulse treatments contained: (1) chickpeas (Primo, Toronto, ON), (2) lentils (Primo, Toronto, ON), (3) navy beans (Ferma, Toronto, ON) or (4) yellow peas (Nupak, Toronto, ON).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary treatment
Description: A within-subject, balanced repeated-measures design was followed where subjects received 4 treatments or control over 5 weeks approximately 1 week apart. The pulse treatments contained: (1) chickpeas (Primo, Toronto, ON), (2) lentils (Primo, Toronto, ON), (3) navy beans (Ferma, Toronto, ON) or (4) yellow peas (Nupak, Toronto, ON).
Study: NCT05342597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: A crossover study in which Japanese healthy subjects receive a single dose of MT-1186 under several dosing condition on Day 1, 3, 5, 7 and 24 according to their treatment sequence.
Study: NCT01410851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary treatment
Description: A within-subject, balanced repeated-measures design was followed where subjects received 4 treatments or control over 5 weeks approximately 1 week apart. The pulse treatments contained: (1) chickpeas (Primo, Toronto, ON), (2) lentils (Primo, Toronto, ON), (3) navy beans (Ferma, Toronto, ON) or (4) yellow peas (Nupak, Toronto, ON).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary treatment
Description: A within-subject, balanced repeated-measures design was followed where subjects received 4 treatments or control over 5 weeks approximately 1 week apart. The pulse treatments contained: (1) chickpeas (Primo, Toronto, ON), (2) lentils (Primo, Toronto, ON), (3) navy beans (Ferma, Toronto, ON) or (4) yellow peas (Nupak, Toronto, ON).
Study: NCT05342597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: A crossover study in which Japanese healthy subjects receive a single dose of MT-1186 under several dosing condition on Day 1, 3, 5, 7 and 24 according to their treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: A crossover study in which Japanese healthy subjects receive a single dose of MT-1186 under several dosing condition on Day 1, 3, 5, 7 and 24 according to their treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: A crossover study in which Japanese healthy subjects receive a single dose of MT-1186 under several dosing condition on Day 1, 3, 5, 7 and 24 according to their treatment sequence.
Study: NCT00330161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study: NCT02433639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302 monotherapy
Description: TH-302 (480 ) mg/m2 D1, D8, D15 Q 4 weeks
Study: NCT01693263

Intervention type: OTHER
Intervention: brachiocephalic fistula (BCF)
Description: We will collect information from physical exams, blood tests, venogram, doppler, vein and artery tissue samples
Study: NCT05681247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe tablet
Description: The subjects randomly received single oral administration of ezetimibe tablet 10 mg
Study: NCT00330161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT05681247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ezetimibe tablet(Ezetrol ®)
Description: The subjects randomly received single oral administration of ezetimibe tablet (Ezetrol ®) 10 mg.
Study: NCT02562118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib + Letrozole
Description: Single agent lenvatinib daily continuously x 2 weeks, followed by letrozole 2.5mg daily + lenvatinib x 12 weeks. Lumpectomy or mastectomy should be considered after completing 14 weeks of pre-operative lenvatinib + letrozole for curative intent in non-metastatic patients and for local control for patients with metastatic disease. If surgery is planned, it should preferably be performed within 2-12 weeks after completing neoadjuvant endocrine therapy, and after toxicities (if any) from the neoadjuvant endocrine therapy have resolved. If the patient is deemed inoperable after 14 weeks of lenvatinib + letrozole, a final biopsy will be obtained, and the patient discontinued from the study and treated as per standard clinical practice by the treating physician.
Study: NCT00523367

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: 24 hour pH testing
Description: 24 hour pH testing will be used to screen patients
Study: NCT01802918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2838232
Description: Bottled powder with 5, 10 and 20mg unit dose strength per single dose for re-constituted oral suspension given once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2838232
Description: Bottled powder with 5, 10 and 20mg unit dose strength per single dose for re-constituted oral suspension given once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Visually matching GSK2838232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Visually matching GSK2838232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100mg tablets once daily for 12 days
Study: NCT02336854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrobell tab. 2mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf cap. 2mg
Study: NCT02252133

Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A contact lenses
Description: Silicone hydrogel contact lenses (8.5 and 8.8 base curves) dispensed per manufacturer's guidelines for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A contact lenses
Description: Silicone hydrogel contact lenses (8.5 and 8.8 base curves) dispensed per manufacturer's guidelines for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Narafilcon A contact lenses
Description: Silicone hydrogel contact lenses (8.5 and 9.0 base curves) dispensed per manufacturer's guidelines for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Narafilcon A contact lenses
Description: Silicone hydrogel contact lenses (8.5 and 9.0 base curves) dispensed per manufacturer's guidelines for daily disposable wear
Study: NCT00003040

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser surgery
Description: CO2 supraglottic laryngectomy within 28 days following registration with neck dissection as needed

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 200 cGy per day, five days per week for approximately 6 weeks, to begin 14 days after laser surgery
Study: NCT00532090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG4733
Description: Administered orally daily at ascending doses to successive cohorts of patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG4733
Description: Administered orally at ascending doses to successive cohorts of patients, on a 3 days on/ 4 days off schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG4733
Description: Administered orally at ascending doses to successive cohorts of patients, on days 1-7 of each 21 day cycle
Study: NCT02561793

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHEA
Description: Women will receive DHEA 12 weeks before starting IVF/ICSI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: women will receive a placebo 12 weeks before starting IVF/ICSI
Study: NCT02148367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin
Description: This is a double blind randomized placebo-cotrolled study. Randomization and blinding will be done by the NIH Pharmacy. Participants and study staff will be blinded as to group assignment.Participants randomized into the placebo group will receive placebo once weekly for 4 weeks. In total, 10 participants will be randomized in this group.~Participants randomized into the experimental group will receive active drug. In total, 20 participants will be randomized in this group. A clinic nurse or physician will administer the study drug, EPO or placebo, to the study participants at the Clinical Center. The study drug is administered by injection under the skin in the arm, leg, or buttock.
Study: NCT05785481

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical and instrumental neurological assessment
Description: During the neonatal period:~neurological objective exam according to the modified Sarnat score, Thompson score and Hammersmith Neonatal Neurological Examination (HINE) within 6 hours of life, 24 hours of life and before resignation; an AEEG study within 6 hours of life, for 6 hours; cerebral ultrasound within 6 hours of life, in the third and seventh day of life; a brain magnetic resonance imaging study between the seventh and 14th day of life; an EEG evaluation within 7 days.~After resignation, all patients will be included in a minimum duration follow-up program of 12 months, with assessments at 3rd, 6th and 12th month of age:~Hammersmith Neonatal Neurological Examination (HINE) and evaluation of the General Movements; evaluation of psychomotor development through Griffiths/Bayley III scales at the 12th month; EEG evaluation at the 6th and 12th month.
Study: NCT02148367

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erythropoietin
Description: This is a double blind randomized placebo-cotrolled study. Randomization and blinding will be done by the NIH Pharmacy. Participants and study staff will be blinded as to group assignment.Participants randomized into the placebo group will receive placebo once weekly for 4 weeks. In total, 10 participants will be randomized in this group.~Participants randomized into the experimental group will receive active drug. In total, 20 participants will be randomized in this group. A clinic nurse or physician will administer the study drug, EPO or placebo, to the study participants at the Clinical Center. The study drug is administered by injection under the skin in the arm, leg, or buttock.
Study: NCT01365156

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraperitoneal laparoscopic lymphadenectomy (EPLND)
Description: Laparoscopic surgical procedure to remove and examine lymph nodes in abdomen, 7-10 days before chemoradiation treatment
Study: NCT00674505

Intervention type: DEVICE
Group type: OTHER
Intervention: Lumen Biomedical FiberNet Embolic Protection System
Description: to demonstrate the safety and filter efficiency of the Lumen Biomedical FiberNet Embolic Protection System during the performance of primary renal stenting in the treatment of pts with a high grade ostial atherosclerotic renal lesion(s).
Study: NCT01985308

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Therapy (MRT)-Active

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magnetic Resonance Therapy (MRT)-Sham
Study: NCT05008640

Intervention type: DEVICE
Intervention: TrueLoo™
Description: TrueLoo™ is an Internet-connected, smart toilet seat that uses computer vision technology to log and capture daily bowel movements and urinations. This data is then categorized by physical excreta characteristics to train and develop machine learning algorithms that are intended to eventually identify significant changes in stool and urine in real-time.
Study: NCT03912337

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once every 4 weeks. SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Erenumab once every 4 weeks. SC injection.
Study: NCT01672515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIPC group
Study: NCT03985878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eteplirsen
Description: Eteplirsen IV infusion once weekly.
Study: NCT01672515

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control group
Study: NCT01155986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 5% medicated plaster
Description: Topical hydrogel plaster (700mg lidocaine)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo topical plaster
Description: Topical hydrogel plaster
Study: NCT00003528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltitrexed
Description: Given IV
Study: NCT01365156

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiation
Description: Radiation for 5 days in a row for 5 to 5½ weeks plus Cisplatin Chemotherapy cisplatin chemotherapy by vein over about 2 hours, 1 time every week for about 6 weeks.
Study: NCT00286754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMI
Description: Stage-matched intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEI
Description: Health Education Intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UC
Description: Usual Care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMI
Description: Stage-matched intervention
Study: NCT01365156

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: Radiation for 5 days in a row for 5 to 5½ weeks plus Cisplatin Chemotherapy cisplatin chemotherapy by vein over about 2 hours, 1 time every week for about 6 weeks.
Study: NCT03729882

Intervention type: PROCEDURE
Group type: OTHER
Intervention: EUS-guided gallbladder drainage
Description: During ERCP evaluation a self-expandable metallic stent will be deployed in the common biliary duct of the patients enrolled in both arms of the present study. A prophylaxis gallbladder drainage will be done using a 3.8 mm working-channel linear-array therapeutic echoendoscope (EG3870UTK;Pentax, Hamburg, Germany) attached to an ultrasound console (Avius Hitachi, Tokyo, Japan) within a transgastric and/or transduodenal approaches to the gallbladder puncture followed by placement of a lumen apposing stent (LAMS) (AXIOS; Xlumena Inc, CA, USA) with a 10 mm luminal diameter and a dumbbell-shaped flanges to bring together the 2 walls in apposition. These feature of the Axios decrease the risk for bile leak, stent migration, and stent occlusion.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non EUS-guided gallbladder drainage
Description: During ERCP evaluation a self-expandable metallic stent will be deployed in the common biliary duct of the patients enrolled in both arms of the present study. If the patient had an acute cholecystitis will be sent to surgery and be considered as a Non EUS-guided gallbladder drainage

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non EUS-guided gallbladder drainage
Description: During ERCP evaluation a self-expandable metallic stent will be deployed in the common biliary duct of the patients enrolled in both arms of the present study. If the patient had an acute cholecystitis will be sent to surgery and be considered as a Non EUS-guided gallbladder drainage
Study: NCT01978002

Intervention type: BEHAVIORAL
Intervention: Pain sensitivity testing

Intervention type: BEHAVIORAL
Intervention: Pain sensitivity testing

Intervention type: BEHAVIORAL
Intervention: Urodynamic testing
Study: NCT03190525

Intervention type: OTHER
Intervention: Quality of life questionnaires
Description: QLQ-C30
Study: NCT00308165

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Convection-Enhanced Delivery
Description: microinfusion pumps to deliver chemotherapy directly into brain tumors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: chemotherapeutic drug for the treatment of brain tumors
Study: NCT03244358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epalrestat
Description: Epalrestat 50mg tid added to standard chemotherapy treatment
Study: NCT04201379

Intervention type: OTHER
Intervention: quality of life assesment
Description: The sociodemographic and clinical characteristics of the individuals who meet the study criteria will be recorded. Evaluations of the participants will be done only once

Intervention type: OTHER
Intervention: quality of life assesment
Description: The sociodemographic and clinical characteristics of the individuals who meet the study criteria will be recorded. Evaluations of the participants will be done only once
Study: NCT05211778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Education Group
Description: Multimedia education provided to the intervention group via a digital tablet
Study: NCT02034487

Intervention type: OTHER
Intervention: retrospective data collection
Study: NCT01965249

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long stitch
Description: AWC with the long stitch technique using MonoMax USP 1, 150 cm loop, HR48 mm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Stitch
Description: Short stitch suture technique using MonoMax USP 2/0, 150 cm, HR26 mm
Study: NCT01908595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M518101
Study: NCT03838484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch, 7 Mg/24 Hr
Description: Nicotine patch, 7 mg/24 hour will be applied to the skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch, 7 Mg/24 Hr
Description: Nicotine patch, 7 mg/24 hour will be applied to the skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch, 7 Mg/24 Hr
Description: Nicotine patch, 7 mg/24 hour will be applied to the skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch, 7 Mg/24 Hr
Description: Nicotine patch, 7 mg/24 hour will be applied to the skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo patch
Description: Placebo skin patch will be applied to the skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo patch
Description: Placebo skin patch will be applied to the skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo patch
Description: Placebo skin patch will be applied to the skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo patch
Description: Placebo skin patch will be applied to the skin.
Study: NCT03898635

Intervention type: DRUG
Intervention: Linezolid
Description: To add linezolid 600mg or 1200mg daily in the initial or subsequent treatment regimen of TBM.

Intervention type: DRUG
Intervention: Linezolid
Description: To add linezolid 600mg or 1200mg daily in the initial or subsequent treatment regimen of TBM.
Study: NCT02794337

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Intervention involves administering high precision radiation to the tumour in 6-8 fractions over 2-2.5 weeks
Study: NCT00286754

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HEI
Description: Health Education Intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: UC
Description: Usual Care